Shilpa Desouza, MD
Pulmonary Disease · Mineola, NYNPI 1588820856
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,681 of the $3,840 with a category attached, or 95.8%. Bayer accounts for 95.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $1,781 and has fallen 88.8% since, to $200 in 2025.
Across 9 payments — averaging $426.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$4K
- Actelion Pharmaceuticals US, Inc.$99
- United Therapeutics Corporation$42
- Electromed, Inc.$19
Across 46 payments — averaging $5921.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$71K
- Actelion Pharmaceuticals, Ltd$65K
- United Therapeutics Corporation$60K
- Insmed, Inc.$31K
- Actelion Pharmaceuticals US, Inc.$24K
- Bayer$23K
What the payments were for
- Consulting fees$3,68196%
- Food & beverage$190%
- Education$1414%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 5 | $3,681 |
| Actelion Pharmaceuticals US, Inc. | 1 | $99 |
| United Therapeutics Corporation | 2 | $42 |
| Electromed, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$3,681
How this compares
$3,840 in reported general payments places this provider in the 70th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 25 | $18,546 |
| XareltoRivaroxaban | 20 | $13,938 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $12,875 |
| Sildenafil Citrate | 15 | $1,724 |
| Torsemide | 75 | $1,363 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $653 |
| Tadalafil | 13 | $622 |
| Spironolactone | 49 | $341 |
| Furosemide | 55 | $232 |
| Montelukast Sodium | 13 | $208 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Mineola
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
- Ali El AtatBrooklyn$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.